目的 探讨苦丹丸联合阿维A胶囊治疗寻常型银屑病的临床疗效。方法 选择新乡市中心医院2019年11月-2020年4月收治的寻常型银屑病患者96例，随机分为对照组和治疗组，每组各48例。对照组口服阿维A胶囊，20 mg/次，1次/d；治疗组在对照组治疗的基础上口服苦丹丸，1袋/次，3次/d。两组患者均治疗8周。观察两组患者临床疗效，同时比较治疗前后两组患者PASI评分、起效时间，及血清炎症因子肿瘤坏死因子-α（TNF-α）、白细胞介素17（IL-17）和白细胞介素23（IL-23）水平。结果 治疗后，对照组和治疗组临床有效率分别为62.50%和83.33%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组PASI评分显著降低（P<0.05），且治疗组PASI评分降低更明显（P<0.05），起效时间更短（P<0.05）。治疗后，两组TNF-α、IL-17、IL-23水平显著降低（P<0.05），且治疗组显著低于对照组（P<0.05）。结论 苦丹丸联合阿维A胶囊治疗寻常型银屑病临床疗效显著，且安全性较高。

Objective To investigate the clinical efficacy of Kudan Pills combined with Acitretin Capsules in treatment of psoriasis vulgaris. Methods Patients (96 cases) with psoriasis vulgaris in Xinxiang Central Hospital from November 2019 to April 2020 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were po administered with Acitretin Capsules, 20 mg/time, once daily. Patients in the treatment group were po administered with Kudan Pills on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the PASI scores, onset time and the serum inflammatory factors levels of TNF-α、IL-17 and IL-23 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 62.50% and 83.33% respectively, and there were differences between two groups (P<0.05). After treatment, the PASI scores in two groups were significantly decreased (P<0.05), and the PASI scores in the treatment group were significantly lower than those in the control group (P<0.05), the onset time in the treatment group was significantly shorter than that in the control group (P<0.05). After treatment, the serum inflammatory factors levels of TNF-α、IL-17 and IL-23 in two groups were significantly decreased (P<0.05), and these factors levels in the treatment group were significantly lower than those in the control group (P<0.05). Conclusions Kudan Pills combined with Acitretin Capsules in treatment of psoriasis vulgaris is efficacy and safety.

R986